Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
Compositions are provided comprising messenger RNA constructs having at least one open reading frame (ORF), wherein the ORF is operatively linked to at least one untranslated region (UTR), wherein the UTR comprises at least one organ protection sequence (OPS), wherein the OPS sequence comprises at least a first, a second and a third micro-RNA (miRNA) target sequence, and wherein each of the at least a first, second and third the miRNA target sequences are optimised to hybridise with a corresponding miRNA sequence. The compositions and molecules provided are useful in therapies such as for the treatment of cancer, in immunotherapies, and in vaccines.
1. A composition comprising:
at least a first mRNA construct comprising at least ene a first open reading frame (ORF), wherein the first ORF encodes an antigen selected from: a bacterial protein and/or a viral protein;
at least a second mRNA construct comprising at least a second open reading frame (ORF), wherein the second ORF encodes a proinflammatory cytokine selected from the group consisting of: IL-1; IL-2; IL-3; IL-4; IL-5; IL-6; IL-7; IL-8; IL-9; IL-10; IL-11; IL-12; IL-15; IL-17; IL-21; TGF-beta; IFNγ; IFNα; IFNβ; TNFα; M-CSF; G-CSF; and GM-CSF, and wherein the second ORF is operatively linked to at least one untranslated region (UTR), wherein the UTR comprises at least a first, second, and a third micro-RNA (miRNA) target sequence, and wherein each of the at least first, second, and third miRNA target sequences are optimised to each hybridise with a different corresponding miRNA sequence; and
an in vivo delivery composition;
wherein the first and second mRNA constructs are comprised within or adsorbed to the delivery composition.
2. The composition of claim 1 , wherein the second ORF codes for an IL-12 protein, or a derivative, agonist or homologue thereof.
3. The composition of claim 2 , wherein the IL-12 protein comprises a human recombinant IL-12 from a single chain (hscIL-12).
4. The composition of claim 1 , wherein the second ORF codes for an IL-7 protein, or a derivative, agonist or homologue thereof.
5. The composition of claim 1 , wherein the second ORF codes for an IL-21 protein, or a derivative, agonist or homologue thereof.
6. The composition of claim 1 , wherein the second ORF codes for an IL-15 protein, or a derivative, agonist or homologue thereof.
7. The composition of claim 1 , wherein the second ORF codes for an IL-17 protein, or a derivative, agonist or homologue thereof.
8. The composition of claim 1 , wherein the second ORF codes for a GM-CSF protein, or a derivative, agonist or homologue thereof.
9. The composition of claim 1 , wherein the at least first, second, and third miRNA target sequences include one or more sequences that bind with an miRNA selected from the group consisting of miRNA-122; miRNA-125; miRNA-199; miRNA-124a; miRNA-126; Let7 miRNA family; miRNA-375; miRNA-141; miRNA-142; miRNA-148a/b; miRNA-143; miRNA-145; miRNA-194; miRNA-200c; miRNA-203a; miRNA-205; miRNA-1; miRNA-133a; miRNA-206; miRNA-34a; miRNA-192; miRNA-194; miRNA-204; miRNA-215; miRNA-30 a,b,c; miRNA-877; miRNA-4300; miRNA-4720; and miRNA-6761.
10. The composition of claim 1 , wherein the at least first, second, and third miRNA target sequences are selected from one or more of the sequences of SEQ ID NOs: 44-57.
11. The composition of claim 1 , wherein the UTR comprises at least a fourth, a fifth and/or a sixth miRNA target sequence, and wherein each of the at least a fourth, fifth and/or sixth miRNA target sequences are optimised to each hybridise with a different corresponding miRNA sequence.
12. The composition of claim 11 , wherein the at least a fourth, fifth and/or sixth miRNA target sequences include one or more sequences that bind with an miRNA selected from the group consisting of miRNA-122; miRNA-125; miRNA-199; miRNA-124a; miRNA-126; Let7 miRNA family; miRNA-375; miRNA-141; miRNA-142; miRNA-148a/b; miRNA-143; miRNA-145; miRNA-194; miRNA-200c; miRNA-203a; miRNA-205; miRNA-1; miRNA-133a; miRNA-206; miRNA-34a; miRNA-192; miRNA-194; miRNA-204; miRNA-215; miRNA-30 a,b,c; miRNA-877; miRNA-4300; miRNA-4720; and miRNA-6761.
13. The composition of claim 11 , wherein the at least a fourth, fifth and/or sixth miRNA target sequences are selected from one or more of the sequences of SEQ ID NOs: 44-57.
14. The composition of claim 1 , wherein the first ORF encodes an antigen comprising all or part of a coronavirus protein.
15. The composition of claim 11 , wherein the coronavirus protein is selected from a coronavirus spike, envelope, membrane, or nucleocapsid protein.
16. The composition of claim 14 , wherein the coronavirus protein is a SARS-CoV-2 spike protein.
17. The composition of claim 1 , wherein the delivery composition is selected from the group consisting of: a lipid nanoparticle; a polymeric particle; a liposome; a lipidoid particle; and a viral vector.
18. The composition of claim 1 , wherein the delivery composition comprises a lipid, phospholipid, cholesterol and a polyethylene glycol (PEG).
19. The composition of claim 1 , wherein the composition comprises at least a third mRNA construct comprising at least a third open reading frame (ORF), wherein the third ORF encodes a further antigen selected from: a bacterial protein and/or a viral protein.
20. A method of stimulating an immune response in a subject comprising administering to the subject in need thereof an effective amount of a composition according to claim 1 .
21. The composition of claim 9 , wherein the at least first, second and third miRNA target sequences comprise sequences that bind to miRNA-122, miRNA-192 and miRNA-30.